RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Background: Circulating tumor cell (CTC) analysis is a promising new diagnostic field for estimating the risk for metastatic relapse and metastatic progression in patients with cancer.
Content: Different analytical systems for CTC isolation and detection have been developed as immunocytochemical and molecular assays, most including separation steps by size or biological characteristics, such as expression of epithelial- or cancer-specific markers. Recent technical advancements in CTC detection and characterization include methods based on multiplex reverse-transcription quantitative PCR and approaches based on imaging and microfilter and microchip devices. New areas of research are directed toward developing novel assays for CTC molecular characterization. QC is an important issue for CTC analysis, and standardization of micrometastatic cell detection and characterization methodologies is important for the incorporation of CTCs into prospective clinical trials to test their clinical utility. The molecular characterization of CTCs can provide important information on the molecular and biological nature of these cells, such as the status of hormone receptors and epidermal and other growth factor receptor family members, and indications of stem-cell characteristics. This information is important for the identification of therapeutic targets and resistance mechanisms in CTCs as well as for the stratification of patients and real-time monitoring of systemic therapies.
Summary: CTC analysis can be used as a liquid biopsy approach for prognostic and predictive purposes in breast and other cancers. In this review we focus on state-of-the-art technology platforms for CTC isolation, imaging, and detection; QC of CTC analysis; and ongoing challenges for the molecular characterization of CTCs.

참고문헌 (Reference)

1 Lianidou ES, "What’s new on circulating tumor cells? A meeting report" 12 : 307-, 2010

2 Fehm T, "Wallwiener D, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RTPCR and comparison to status of bone marrow disseminated cells" 11 : 59-, 2009

3 Magnifico A, "Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab" 15 : 2010-2021, 2009

4 Bozionellou V, "Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer" 10 : 8185-8194, 2004

5 Diehn M, "Therapeutic implications of the cancer stem cell hypothesis" 19 : 78-86, 2009

6 Fidler IJ, "The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited" 3 : 453-458, 2003

7 Bustin SA, "The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments" 55 : 611-622, 2009

8 Aktas B, "Stem cell and epithelialmesenchymal transition markers are frequentlyoverexpressed in circulating tumor cells of metastatic breast cancer patients" 11 : 46-, 2009

9 Tibbe AG, "Statistical considerations for enumeration of circulating tumor cells" 71 : 154-162, 2007

10 Pachmann K, "Standardized quantification of circulating peripheral tumor cells from lung and breast cancer" 43 : 617-627, 2005